首页> 外文OA文献 >Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada

【2h】

Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada

机译：在加拿大模拟人乳头瘤病毒（HPV）-16/18 AS04辅助疫苗和人乳头瘤病毒（HPV）-6/11/16/18疫苗交叉保护数据差异的影响

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Michele Kohli; Donna Lawrence; Jennifer Haig; Andrea Anonychuk; Nadia Demarteau;
展开▼
作者单位

展开▼
年度 2012
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada [J] . Michele Kohli, Donna Lawrence, Jennifer Haig, BMC Public Health . 2012,第1期

机译：在加拿大模拟人乳头瘤病毒（HPV）-16/18 AS04辅助疫苗和人乳头瘤病毒（HPV）-6/11/16/18疫苗交叉保护数据差异的影响
2. Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: End-of-study analysis of a Phase III randomized trial [J] . Einstein Mark H., Takacs Peter, Chatterjee Archana, Human vaccines & immunotherapeutics. . 2014,第12期

机译：18-45岁健康女性中人乳头瘤病毒（HPV）-16/18 AS04辅助疫苗和HPV-6 / 11/16/18疫苗的长期免疫原性和安全性比较： III期随机试验
3. Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: Follow-up through Month 48 in a Phase III randomized study [J] . Einstein Mark H., Levin Myron J., Chatterjee Archana, Human vaccines & immunotherapeutics. . 2014,第12期

机译：18-45岁健康女性中人乳头瘤病毒（HPV）-16/18 AS04辅助疫苗和HPV-6 / 11/16/18疫苗的体液和细胞免疫原性和安全性比较：随访至第48个月III随机研究
4. The synthesis and immunological activity of a lipid-core peptide(LCP)based Human Papillomavirus(HPV)type-16 vaccine [C] . Peter M.Moyle, Colleen Olive, Hsien Sun International Peptide Symposium;European Peptide Symposium . 2005

机译：脂质肽（LCP）人乳头瘤病毒（HPV）型16型疫苗的合成和免疫活性
5. A Multiplexed Human Papillomavirus (HPV) 16 and 18 Diagnostic for Cervical Cancer Screening [D] . Wong, Winnie S. 2019

机译：多重人类乳头瘤病毒（HPV）16和18诊断宫颈癌筛查
6. Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada [O] . Michele Kohli, Donna Lawrence, Jennifer Haig, 2012

机译：在加拿大模拟人乳头瘤病毒（HPV）-16/18 AS04辅助疫苗和人乳头瘤病毒（HPV）-6/11/16/18疫苗交叉保护数据差异的影响
7. Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada [O] . Kohli Michele, Lawrence Donna, Haig Jennifer, 2012

机译：模拟人类乳头瘤病毒（HpV）-16/18 as04佐剂疫苗与加拿大人乳头瘤病毒（HpV）-6/11/16/18疫苗之间交叉保护数据差异的影响

Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada

著录项

引文网络

相似文献

相关主题

期刊订阅